A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/00 (2006.01)
Patent
CA 2596714
The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
L'invention concerne des méthodes de traitement du cancer résistant au gefitinib et/ou à l'erlotinib. Un contrôle est effectué sur un individu atteint d'un cancer afin de surveiller la progression de la maladie après un traitement faisant intervenir du gefitinib et/ou de l'erlotinib. La progression du cancer indique que le cancer résiste au gefitinib et/ ou à l'erlotinib. Après la prise en compte de la progression de cancer, on administre au sujet une composition pharmaceutique comprenant un inhibiteur irréversible du récepteur du facteur de croissance épidermique (EGFR). Dans des modes de réalisation préférés, l'inhibiteur irréversible du EGFR est un inhibiteur de type EKB-569, HKI-272 et HKI-357.
Bell Daphne Winifred
Godin-Heymann Nadia G.
Haber Daniel
Kwak Eunice L.
Rabindran Sridhar Krishna
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
The General Hospital Corporation
Wyeth
LandOfFree
Method for treating gefitinib resistant cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating gefitinib resistant cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating gefitinib resistant cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2024869